The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors

Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results: In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford-able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or lab-oratory tests

Otel İşletmelerinde Kurumsal Sosyal Sorumluluk Uygulamaları: Kuşadası Örneği

İşletmeler kar elde etmek ve büyümek gibi amaçları dışında aynı zamanda toplumsal faydalar sağlamayı  amaçlamaktadırlar. Tüketici kitlesinin bilinçlenmesi sonucunda işletmeler son yıllarda KSS faaliyetlerini rekabet ve imaj oluşturma stratejileri içerisinde değerlendirmeye başlamışlardır. Konaklama işletmelerinde ise özellikle uluslararası otel zincirlerinde KSS uygulamalarının önemli bir role sahip olduğu görülmektedir. Konaklama işletmelerinde de diğer işletmelerde olduğu gibi KSS motivasyonlarının rekabet avantajı sağlamak, çevresel ve sosyal katkı sağlamak üzerine odaklandığı görülmektedir. Çalışmada konaklama işletmelerinin KSS faaliyetlerinin neler olduğunun belirlenmesi amaçlanmıştır. Çalışmada yarı yapılandırılmış görüşme yöntemini kullanılmıştır. Kuşadası bölgesinde 5 yıldızlı konaklama işletmeleri yöneticileri ile yapılan görüşmeler sonucunda konaklama işletmelerinin KSS faaliyetlerine yer verdikleri ve genel olarak daha çok toplumsal ve çevresel faaliyetlere yöneldikleri görülmüştür

Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

This study was designed to evaluate the tolerability and therapeutic activity of paclitaxel and carboplatin combination therapy followed by radical thoracic radiotherapy with a concomitant boost technique with concurrent weekly paclitaxel in good performance status of patients with stage IIIA and IIIB non-small cell lung cancer. Patients with newly diagnosed inoperable non-small cell lung cancer received paclitaxel (100 mg/m(2)) as a 1-h infusion on d 1,8,15,28,35, and 42. Carboplatin (area under the curve of 6) was given as a 30-min infusion on d 1 and 28. Radiotherapy commenced on d 49 and was delivered with accelerated fractionation with concomitant boost at 1.8 Gy/fraction/d, 5 d/week and 1.5 Gy/fraction/d to a boost field as a second daily treatment for the last 10 treatment days to 60 Gy/35 fractions/5 wk. During radiation treatment, paclitaxel (60 mg/m2) was given as a 1-h infusion once weekly for 5 wk. Twenty-four patients were enrolled in the study. Hematologic toxicities and alopecia were the major acute toxicities during induction chemotherapy; 8.7% of the patients experienced grade 3-4 neutropenia and alopecia. The main acute toxicity of concurrent chemoradiotherapy was esophagitis; grade 3 esophagitis was documented in 23.5% of the patients. No major late toxicity was seen. Overall response rate to the treatment was 65.2%. The median and 1-yr overall-survival rates were 24.9 mo and 63.8%, respectively. The median and 1-yr progression-free survival rates were 9.0 mo and 27.8%, respectively. The main acute toxicities were hematologic toxicity, esophagitis, and alopecia. The response rate and the survival rates achieved with this treatment regimen are particularly noteworthy, especially considering the advanced stage of the patients treated

Mimarlık Doktora Eğitiminde Yapı Atölyesi: Alaçatı

Dokuz Eylül Üniversitesinde yürütülen "yapı atölyesi" dersi yıllardır doktora düzeyinde öğretilen derslerden biridir.</p

Thymidine labeling index in epithelial ovarian cancer

Objective: The aim of this study is to determine the thymidine labeling index and its prognostic role in patients with ovarian cancer. Methods: Tumor cell proliferation in 32 patients with primary ovarian cancer admitted to Istanbul Medical Faculty, Department of Obstetrics and Gynecology, between 1993 and 1997 was investigated using the [H-3]thymidine labeling index (TLI). TLI results were compared with other clinical and histopathologic prognostic parameters. Results: The mean and median TLI values of the patients were 9.3 +/- 6.2% and 9.20% (range: 0.4-23.0%), respectively. Sixteen patients showed high proliferation rates (mean TLI: 14.3%). These patients had an overall survival rate of 46.7% at 3 years. The mean TLI level and overall survival at 3 years in the low proliferation rate group were 4.4 and 68.8%, respectively. Patients with a high TLI had a significantly shorter survival compared to those with a low TLI (P 0.05). However, there was no statistically significant correlation between TLI and other prognostic parameters. Conclusion: TLI may have a predictive value in determining the outcome of patients with ovarian cancer. Further larger scale studies are needed before definite conclusions can be made about its role as a prognostic factor in this disease. (C) 2001 International Federation of Gynecology and Obstetrics. All rights reserved

Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group

The aim of this study was to investigate the therapeutic outcome and prognostic factors in 36 patients with resectable thymoma who were referred to our clinic following surgical resection. The median age was 45 years, ranging from 19 to 72 years. Myastenia gravis was observed in 28 patients (77.7%). The most frequent histologic subtype was epithelial (n = 21, 58.3%), followed by the lymphocytic type (n = 6, 16.7%). Stage at presentation was distributed as stage 1, 2 patients (2.7%); stage 2, 19 patients (52.8%); stage 3, 10 (27.8%); and stage 4, 3 patients (8.3%). The majority of the patients (n = 32, 88.9%) had completely resectable disease, whereas 2 patients had microscopic and 2 more patients had macroscopic residual disease after surgery. Adjuvant radiotherapy was administered to 28 patients. After a median follow-up period of 39 months, 5 patients (16.1%) experienced recurrence. There was a significant negative correlation between recurrence and adjuvant radiation therapy (two-sided p = 0.0001). There were no objective responses to chemotherapy given to 4 patients for recurrent disease. Overall survival (OS) and progression-free survival (PFS) was 82.8% and 76.6% at 5 years, respectively. Adjuvant radiotherapy had a significant association with both OS (p = 0.039) and PFS (p = 0.00001). Furthermore, recurrent disease was observed to have a significant negative impact on OS (p = 0.039). The results of this study suggest that adjuvant radiotherapy may provide survival benefit in patients with resectable thymoma, regardless of surgical margins

Clinicopathological data's of advanced NSCLC patients with ROS1 gene rearrangement and of clinical responses to crizotinib in Turkey

WOS: 000370365103329